Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination.

Locher CP, Grant RM, Collisson EA, Reyes-Terán G, Elbeik T, Kahn JO, Levy JA.

AIDS Res Hum Retroviruses. 1999 Dec 10;15(18):1685-9.

PMID:
10606091
2.

Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative.

Bartlett JA, Wasserman SS, Hicks CB, Dodge RT, Weinhold KJ, Tacket CO, Ketter N, Wittek AE, Palker TJ, Haynes BF.

AIDS. 1998 Jul 30;12(11):1291-300.

PMID:
9708408
3.

Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.

Connor RI, Korber BT, Graham BS, Hahn BH, Ho DD, Walker BD, Neumann AU, Vermund SH, Mestecky J, Jackson S, Fenamore E, Cao Y, Gao F, Kalams S, Kunstman KJ, McDonald D, McWilliams N, Trkola A, Moore JP, Wolinsky SM.

J Virol. 1998 Feb;72(2):1552-76.

5.

Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model.

Page M, Stebbings R, Berry N, Hull R, Ferguson D, Davis L, Duffy L, Elsley W, Hall J, Ham C, Hassall M, Li B, Mee ET, Quartey-Papafio R, Rose NJ, Mathy N, Voss G, Stott EJ, Almond N.

Retrovirology. 2012 Jul 16;9:56. doi: 10.1186/1742-4690-9-56.

7.

Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.

Letvin NL, Robinson S, Rohne D, Axthelm MK, Fanton JW, Bilska M, Palker TJ, Liao HX, Haynes BF, Montefiori DC.

J Virol. 2001 May;75(9):4165-75.

8.

Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.

Nehete PN, Chitta S, Hossain MM, Hill L, Bernacky BJ, Baze W, Arlinghaus RB, Sastry KJ.

Vaccine. 2001 Dec 12;20(5-6):813-25.

PMID:
11738745
9.

Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.

Corey L, McElrath MJ, Weinhold K, Matthews T, Stablein D, Graham B, Keefer M, Schwartz D, Gorse G.

J Infect Dis. 1998 Feb;177(2):301-9.

10.

HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.

Bruck C, Thiriart C, Fabry L, Francotte M, Pala P, Van Opstal O, Culp J, Rosenberg M, De Wilde M, Heidt P, Heeney J.

Vaccine. 1994 Sep;12(12):1141-8.

PMID:
7998425
12.

Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.

Bures R, Gaitan A, Zhu T, Graziosi C, McGrath KM, Tartaglia J, Caudrelier P, El Habib R, Klein M, Lazzarin A, Stablein DM, Deers M, Corey L, Greenberg ML, Schwartz DH, Montefiori DC.

AIDS Res Hum Retroviruses. 2000 Dec 10;16(18):2019-35.

PMID:
11153085
13.

Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons.

Haigwood NL, Nara PL, Brooks E, Van Nest GA, Ott G, Higgins KW, Dunlop N, Scandella CJ, Eichberg JW, Steimer KS.

J Virol. 1992 Jan;66(1):172-82.

14.

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.

Salmon-Céron D, Excler JL, Finkielsztejn L, Autran B, Gluckman JC, Sicard D, Matthews TJ, Meignier B, Valentin C, El Habib R, Blondeau C, Raux M, Moog C, Tartaglia J, Chong P, Klein M, Milcamps B, Heshmati F, Plotkin S.

AIDS Res Hum Retroviruses. 1999 May 1;15(7):633-45.

PMID:
10331442
15.

Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines.

Montefiori DC, Metch B, McElrath MJ, Self S, Weinhold KJ, Corey L; HIV Vaccine Trials Network..

J Infect Dis. 2004 Dec 1;190(11):1962-9.

16.

Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals.

Honda M, Matsuo K, Nakasone T, Okamoto Y, Yoshizaki H, Kitamura K, Sugiura W, Watanabe K, Fukushima Y, Haga S, Katsura Y, Tasaka H, Komuro K, Yamada T, Asano T, Yamazaki A, Yamazaki S.

Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10693-7.

17.

Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.

Kang CY, Luo L, Wainberg MA, Li Y.

Biol Chem. 1999 Mar;380(3):353-64.

PMID:
10223338
18.

Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.

Gorse GJ, Patel GB, Newman FK, Belshe RB, Berman PW, Gregory TJ, Matthews TJ.

Clin Diagn Lab Immunol. 1996 Jul;3(4):378-86.

19.
Items per page

Supplemental Content

Support Center